• Advocacy Guidance Brief - Funding

    This is the Collective's Advocacy Guidance Brief on increasing investment in programmes and policies that protect, promote, and support breastfeeding.

    Breastfeeding is a smart investment that saves lives and benefits the economy. The current global level of investment is not enough to substantially increase and sustain breastfeeding rates. Governments and political leaders should invest in comprehensive strategies and social policies that protect, promote, and support breastfeeding to ensure the health and prosperity of generations to come.

  • Cost of Not Breastfeeding Tool

    This tool was created by Alive & Thrive to help determine the future economic losses of low- and middle-income countries due to not breastfeeding according to recommendations. All monetary values are presented in US dollars. 

  • HIV Prevention Research & Development Investments, 2000-16: Investment Priorities to Fund Innovation in a Challenging Global Health Landscape

    This annual accounting of funding for biomedical HIV prevention research tracks trends and identifies gaps in investment. In 2016, funding for HIV prevention R&D decreased by US$35 million from the previous year to a total of US$1.17 billion — the lowest recorded annual investment in more than a decade. A link to the full archive of past resource tracking reports is provided.

  • HIV Prevention on the Line: Executive Summary

    Published in advance of the full version of AVAC's report for 2014-15, this four-page document summarises the state of HIV prevention research and implementation and the targets, strategies, and resources needed to end the AIDS epidemic.

  • Multipurpose Prevention Technologies for the Developing World: U.S. Investment is Critical

    Published in the Guttmacher Policy Review in the summer of 2015, this article makes the case for greater investment in the development of multipurpose prevention technologies (MPTs) that would provide protection against multiple health risks, such as unintended pregnancy, HIV, and sexually transmitted infections. No large pharmaceutical company has a significant program in MPT research, so the development of these promising products depends on support from governments and foundations.